Prehypertension: A possible target for antihypertensive medication

被引:14
作者
Nesbitt S.D. [1 ]
Julius S. [1 ]
机构
[1] Division of Hypertension, University of Michigan, Medical Center, Ann Arbor, MI 48109-0356
关键词
Angiotensin Converting Enzyme Inhibitor; Candesartan; Clinical Hypertension; Borderline Hypertension; Adequate Blood Pressure Control;
D O I
10.1007/s11906-000-0038-7
中图分类号
学科分类号
摘要
Vascular changes associated with elevated blood pressure may precede the clinical diagnosis of hypertension. Even after the diagnosis is made, associated coronary heart disease and renal disease continue to progress, despite adequate blood pressure control. Early treatment of blood pressure may reduce the incidence of clinical hypertension and reduce the long-term consequences of hypertension. Animal studies have shown that early blood pressure lowering, through blockade of the renin-angiotensin system, prevents long-term hypertension. Prevention is an important goal in the treatment of hypertension. Our best attempts to prevent hypertension use nonpharmacologic methods of diet and exercise. These methods are fraught with difficulties of implementation and compliance that limit their success. Finding novel approaches to prevent hypertension may have a major impact on the incidence of hypertension. We are investigating the effect of 2 years of treatment with an angiotensin receptor blocker (candesartan cilexitil) compared with placebo, followed by 2 years of follow-up, on the incidence of hypertension in patients with high-normal blood pressure. Incidence of hypertension after discontinuation of active treatment will be compared with the incidence in the placebo group. There will be 1000 patients enrolled in the study, which will be completed in 2004. Copyright © 2000 by Current Science Inc.
引用
收藏
页码:356 / 361
页数:5
相关论文
共 30 条
[1]  
Julius S., Schork M.A., Borderline hypertension: A critical review, J Chronic Dis, 23, pp. 723-754, (1971)
[2]  
Johansen P.L., Central haemodynamics in essential hypertension at rest and during exercise: A 20 year follow up study, J Hypertens, 7, SUPPL. 6, (1989)
[3]  
Leitschuh M., Cupples L.A., Kannel W., Et al., High-normal blood pressure progression to hypertension in the Framingham heart study, Hypertension, 17, pp. 22-27, (1991)
[4]  
The trials of hypertension prevention collaborative research group: Effects of weight loss and sodium reduction interven tion on blood pressure and hypertension incidence in overweight people with high normal blood pressure, Arch Intern Med, 157, pp. 657-667, (1997)
[5]  
Folkow B., Physiological aspects of primary hypertension, Physiol Rev, 62, pp. 347-503, (1982)
[6]  
Conway J., A vascular abnormality in hypertension. A study of blood flow in the forearm, Circulation, 27, pp. 520-529, (1963)
[7]  
Sivertsson R., The hemodynamic importance of structural vascular changes in essential hypertension, Acta Physiol Scand, 79, SUPPL. 343, pp. 3-56, (1970)
[8]  
Egan B., Panis R., Hinderliter A., Et al., Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension, J Clin Invest, 80, pp. 812-817, (1987)
[9]  
Philipp T.H., Distler A., Cordes U., Sympathetic nervous system and blood pressure control in essential hypertension, Lancet, 2, pp. 959-963, (1978)
[10]  
Sivertsson R., Andersson O., Hansson L., Blood pressure reduction and vascular adaptation. A study on long term effects of treatment with mefruside or atenolol, Acta Med Scand, 205, pp. 477-482, (1979)